Private Equity Dashboard:
Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!
Phosplatin Therapeutics completes USD18.4m private financing round
Submitted 26/08/2020 - 4:20pmPhosplatin Therapeutics, a clinical stage pharmaceutical company focused on oncology therapeutics, has completed an oversubscribed USD18.4 million private financing round.
Participation included new and existing investors, inclusive of family offices from the US, Europe and Asia-Pacific, and high net worth individuals.
Robert Fallon, President and Chief Executive Officer of Phosplatin Therapeutics, says: "The success of the financing underscores the breadth of our data from three different Phase I trials and the broad potential of our lead compound, PT-112, which is advancing through clinical development as a monotherapy, including in mCRPC and multiple myeloma, and in combination with PD-L1 immune checkpoint inhibition. We plan to utilise the proceeds of this capital raise to complete Phase 2 development of PT-112, and our continued planning prior to launching intended pivotal trials."
Phosplatin Therapeutics has raised USD56 million in equity capital since inception, and receives milestone fees from its sub-licensee for Greater China.
Tags Deals & Transactions InvestmentsToday's Private Equity Headlines:
Access Over 250K+ Industry Headlines, Posts and Updates
Join AlphaMaven
The Premier Alternative Investment
Research and Due Diligence Platform for Investors
Free Membership for Qualified Investors and Industry Participants
- Easily Customize Content to Match Your Investment Preferences
- Breaking News 24/7/365
- Daily Newsletter & Indices
- Alternative Investment Listings & LeaderBoards
- Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
- Company Directory
- Contact Directory
- Member Posts & Publications
- Alpha University Video Series to Expand Investor Knowledge
- AUM Accelerator Program (designed for investment managers)
- Over 450K+ Industry Headlines, Posts and Updates
